DLBCL survival improved with novel antibody-drug conjugateJune 17, 2018Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Chemo-free regimen appears viable in previously untreated FLJune 7, 2018Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Novel antibody shifts ‘eat me/don’t eat me’ balance in refractory NHLJune 6, 2018Immuno-oncologyLymphoma & Plasma Cell DisordersFollicular Lymphoma
Early results favor combo IL-15/anti-CD20 in indolent NHLMay 3, 2018Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Novartis CAR T-cell therapy adds a lymphoma indicationMay 3, 2018Lymphoma & Plasma Cell DisordersFollicular Lymphoma
FDA places partial hold on trials after secondary lymphomaApril 25, 2018Lymphoma & Plasma Cell DisordersFollicular Lymphoma
FDA grants priority review of follicular lymphoma drugApril 11, 2018Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Experimental voxtalisib shows mixed results in phase 2 studyMarch 22, 2018Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Outpatient CAR T infusions feasible using liso-celMarch 12, 2018Lymphoma & Plasma Cell DisordersImmunotherapyFollicular Lymphoma
Best options for treating relapsed/refractory PTCLMarch 8, 2018Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Basiliximab/BEAM may improve post-ASCT outcomes in PTCLFebruary 21, 2018Lymphoma & Plasma Cell DisordersFollicular Lymphoma
TRANSCEND NHL trial identifies window for CAR T expansionFebruary 6, 2018Lymphoma & Plasma Cell DisordersFollicular Lymphoma
BTK inhibitor zanubrutinib active in non-Hodgkin lymphomasJanuary 2, 2018Lymphoma & Plasma Cell DisordersFollicular Lymphoma
VIDEO - New lymphoma drug approvals: Clinical use, future directionsDecember 14, 2017Lymphoma & Plasma Cell DisordersImmuno-oncologyFollicular Lymphoma
